MAOB and Parkinson disease: Safinamide is the first PD medication having a double mechanism of action, being a reversible monoamine oxidase-B inhibitor (MAOB-i) and a glutamate release modulator through use-dependent sodium and N-type calcium channel blockade [7–10], which differentiate this therapeutic option from the other available MAOB-I on the market, selegiline and rasagiline.